查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1999384

微創胸腔外科手術市場：依手術類型、產品類型、適應症及最終用戶分類－2026-2032年全球市場預測

Minimally Invasive Thoracic Surgery Market by Procedure Type, Product Type, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，微創胸腔外科手術市場價值將達到 29.5 億美元，到 2026 年將成長至 31.9 億美元，到 2032 年將達到 51.8 億美元，複合年成長率為 8.35%。

主要市場統計數據
基準年 2025 29.5億美元
預計年份：2026年 31.9億美元
預測年份：2032年 51.8億美元
複合年成長率 (%) 8.35%

本文簡要概述了手術流程、產品和醫療機構的發展趨勢如何融合，從而重新定義胸腔外科的病患照護管道和臨床重點。

胸腔外科微創手術正進入一個重塑手術流程和病人預後的階段，這個階段融合了科技、醫療機構的優先事項。過去十年，外科醫生和醫院系統穩步擴大微創手術的應用範圍，以減少手術全期併發症、縮短復原時間並提高病患滿意度。這種轉變不僅反映了不斷發展的臨床證據，也得益於可視化技術、器械和平台整合方面的進步，這些進步使得更小的手術網路基地台和更精準、更複雜的胸腔外科手術成為可能。

整合平台的發展、外科技術的演進以及醫療模式的去中心化是如何共同作用，重塑胸腔外科手術實踐和採購政策的？

由於技術、臨床和操作趨勢的融合，胸腔外科領域正經歷著變革性的轉變。首先，機器人平台的成熟提高了手術操作性和3D視覺化能力，改變了複雜切除術的標準。因此，先前受限的微創手術適應症得以擴展。單孔手術技術的改進和視訊輔助內視鏡技術的進步進一步推動了這一發展，使外科醫生能夠根據臨床目標和醫療機構的能力選擇合適的手術方案。

為因應影響採購、製造夥伴關係和合約價值模型的價格變動，價值鏈調整和籌資策略。

2025年生效的關稅調整將成為影響整個醫療保健生態系統供應鏈策略、採購時機和成本轉移的重要外部因素。為此，製造商和醫療保健採購團隊正在重新審視其採購地點和庫存政策，以降低進口關稅上漲帶來的風險，並確保關鍵物資的持續供應。這促使人們更加關注近岸外包、供應商網路多元化以及重新談判合約條款，這些條款強調總體擁有成本（TCO）而非僅僅是單價。

詳細的細分觀點用於闡明實施情況，將程序選擇、醫療設備模式的細微差別、醫療機構要求和特定應用的臨床需求連結起來。

細分市場分析概述了理解不同手術類型、產品類型、最終用戶、技術和應用領域中差異化採用模式、臨床適用性和購買行為的觀點。在考慮手術類型時，臨床醫生會權衡機器人輔助胸腔鏡、單孔胸腔鏡輔助手術 (VATS) 和影片輔助胸腔鏡之間的利弊，並平衡精度、學習曲線和手術室空間需求等因素，以確定最適合其醫療機構病例組合的方案。產品系列的選擇也需要類似的細緻判斷。高精度雙極電凝、電外科和超音波系統等能量器械的選擇是基於其止血性能和熱特性，而解剖器、抓鉗和剪刀等器械則根據其人體工學設計和與手術孔徑的匹配度進行評估。縫合器和拋棄式產品仍然是組織切割和吻合的必需品，而從高清平台到 3D 內視鏡和 2D 內視鏡等視覺化系統，對術中決策和培訓過程有著顯著的影響。

全球醫療保健系統和採購實際情況的區域差異如何影響技術採用、培訓重點和商業化策略？

區域趨勢影響著美洲、歐洲、中東和非洲以及亞太地區的技術傳播、報銷管道和採用率，每個地區都有其獨特的結構性因素。在美洲運作的相關人員常常面臨複雜的環境：高度專業化的三級醫療機構主導機器人手術和單孔手術的普及，而區域性醫院和門診中心則在評估經濟高效的器械平台，以拓展微創手術。該地區的報銷模式影響著採購週期以及對承諾提升營運效率的資本密集系統的投資意願。

競爭格局洞察揭示了夥伴關係為主導的策略，這些策略定義了平台現有的優勢、獨特的創新和差異化的市場定位。

該領域的競爭格局呈現出多元化的格局，既有成熟的平台供應商，也有專業器材製造商，還有在能量、縫合和視覺化領域提供創新技術的新興企業公司。領先的平台供應商持續投資於模組化和互通性，以降低廠商鎖定風險並擴大臨床應用範圍。同時，專業公司則專注於差異化的性能特徵，例如先進的能量曲線、超薄縫合技術或超高清3D成像，以期在特定外科領域贏得市場佔有率。

醫療設備開發商和醫療保健系統可採取的策略重點，以將技術能力轉化為永續的臨床部署和商業性韌性。

產業領導者應優先考慮將技術開發、經營模式和臨床部署流程結合的策略，以加速永續應用。首先，投資於互通性和模組化架構，使器械和耗材能夠在多個平台和手術方法中使用，從而降低醫院的轉換成本，並促進社區和高級醫療機構的更廣泛應用。其次，開發完善的培訓和認證項目，結合模擬、導師指導和市場後分析，以縮短外科醫生採用機器人手術、單孔手術或高度視訊輔助手術技術的學習曲線。

為了獲得實際的見解，我們採用了一種綜合的混合方法，將與主要相關人員的對話、臨床證據審查、醫療設備評估和供應鏈分析結合起來。

本研究採用混合方法，結合對關鍵相關人員的訪談、臨床文獻回顧、醫療設備和技術評估以及供應鏈分析，對微創胸腔外科手術進行了綜合分析，從而提供了全面的觀點。主要受訪者包括外科負責人、醫院採購經理、門診手術中心管理人員以及醫療設備製造商的產品經理，旨在了解實際決策標準、推廣應用障礙以及服務期望。臨床文獻回顧著重於比較研究、手術流程說明和安全性分析，以闡明手術選擇如何影響治療結果和工作流程。

一種具有前瞻性的綜合方法，強調將醫療設備設計、臨床培訓和商業性適用性相結合，以確保廣泛和永續的應用。

總體而言，微創胸腔外科手術正處於一個轉折點，醫療設備的創新、手術技術的改進以及醫療服務模式的變革共同塑造著其未來的發展方向。手術技術的選擇、產品功能以及醫療服務提供者的準備之間的相互作用，不僅決定臨床結果，也決定技術應用的速度和規模。隨著供應鏈壓力和關稅變化影響商業性趨勢，相關人員必須採取綜合策略，協調採購、培訓和臨床管治。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 微創胸腔外科市場：依手術類型分類

  • 肺切除術
    • 切除術
    • 切除術
    • 楔形切除術
    • 全肺切除術
    • 肺減容手術
  • 食道手術
    • 切除術
    • 抗逆流手術
    • 肌切開術
  • 縱膈手術
    • 胸腺切除術
    • 縱膈腫瘤切除術
    • 淋巴結清除術
  • 胸膜手術
    • 胸膜固定術
    • 胸膜分離
    • 切除術
    • 胸膜切片檢查
  • 交感神經手術

第9章 微創胸腔外科市場：依產品類型分類

  • 外科系統
    • 胸腔鏡視訊系統
    • 機器人手術平台
  • 手術器械
    • 內視鏡手用器械
    • 內視鏡吻合器
    • 能源設備
      • 電外科設備
      • 超音波設備
      • 先進的雙極裝置
    • 吸塵和清潔設備
  • 存取裝置
    • 套管針和港口
    • 穿刺針
    • 傷口保護材料
  • 封堵和止血產品
    • 縫線和夾子
    • 釘線加固
    • 密封劑和止血劑
  • 影像導航
    • 術中影像系統
    • 螢光成像系統
    • 導航地圖系統

第10章 微創胸腔外科市場：依適應症分類

  • 惡性胸腔疾病
    • 原發性肺癌
      • 早期非小細胞肺癌
      • 局部晚期非小細胞肺癌
    • 肺轉移性病變
    • 食道癌
    • 縱膈惡性腫瘤
  • 健康胸部疾病
    • 氣胸
    • 積膿
    • 食道良性疾病
      • 胃食道逆流症
      • 賁門失弛症
    • 縱膈囊腫和良性腫瘤
    • 多汗症
    • 良性肺結節

第11章 微創胸腔外科市場：依最終用戶分類

  • 醫院
    • 三級醫療機構
    • 當地醫院
    • 專業胸腔科中心
  • 門診手術中心
  • 專科診所
  • 學術研究機構

第12章 微創胸腔外科市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 微創胸腔外科市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 微創胸腔外科手術市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國微創胸腔外科市場

第16章：中國微創胸腔外科手術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardio Medical GmbH
  • CONMED Corporation
  • Cook Medical LLC
  • Dextera Surgical, Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare, Inc.
  • Grena Ltd.
  • Intuitive Surgical, Inc.
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Koninklijke Philips NV
  • LivaNova plc
  • Medela Healthcare
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • Sklar Surgical Instruments
  • Smith & Nephew plc
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
Product Code: MRR-3A2E844FEF43

The Minimally Invasive Thoracic Surgery Market was valued at USD 2.95 billion in 2025 and is projected to grow to USD 3.19 billion in 2026, with a CAGR of 8.35%, reaching USD 5.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.95 billion
Estimated Year [2026] USD 3.19 billion
Forecast Year [2032] USD 5.18 billion
CAGR (%) 8.35%

Concise framing of how procedural, product, and institutional dynamics converge to redefine patient pathways and clinical priorities in thoracic surgery

Minimally invasive approaches to thoracic surgery have entered a phase where technique, technology, and institutional priorities intersect to reshape surgical pathways and patient outcomes. Over the past decade, surgeons and hospital systems have steadily expanded adoption of less invasive procedures to reduce perioperative morbidity, shorten recovery timelines, and improve patient satisfaction. This shift reflects not only evolving clinical evidence but also advances in visualization, instrumentation, and platform integration that enable complex thoracic procedures to be executed with smaller access points and enhanced precision.

In practice, procedure type choices have broadened to include an array of options-ranging from robotic assisted thoracoscopic surgery to uniportal approaches and conventional video-assisted techniques-each offering distinct clinical trade-offs and workflow implications. Concurrently, product innovation has centered on energy devices, refined instruments, staple systems and advanced visualization solutions, creating a richer ecosystem for surgical teams to optimize techniques and outcomes. End-user dynamics have been shaped by ambulatory surgical centers seeking efficient, same-day workflows while hospitals continue to balance community-level procedural demand with tertiary care complexity. Technology architectures, spanning multi-port to single-port and robotic systems, respond to institutional priorities for cost, scalability, and clinical versatility.

As stakeholders evaluate investment and adoption strategies, attention increasingly falls on how procedural selection, device compatibility, and facility readiness converge to define pathways of care. This executive summary synthesizes those converging forces and frames implications for clinical leaders, hospital administrators, device manufacturers, and policy-makers aiming to align innovation with sustainable clinical value.

How integrated platform advancements, procedural technique evolution, and care model decentralization are jointly reshaping thoracic surgery practice and procurement choices

The landscape for thoracic surgery is undergoing transformative shifts driven by converging technological, clinical, and operational trends. First, maturation of robotic platforms has altered the calculus for complex resections by improving dexterity and three-dimensional visualization, which in turn has expanded indications where minimally invasive approaches were previously constrained. This evolution is complemented by refinement in uniportal techniques and enhancements in video-assisted endoscopy, enabling surgeons to select an approach that matches clinical goals and institutional capacity.

Second, device-level innovation has accelerated the transition from single-function tools to integrated systems that combine energy delivery, precision dissection, and stapling within a cohesive procedural workflow. Advanced bipolar and ultrasonic energy modalities address hemostasis and tissue handling in ways that reduce collateral thermal injury and streamline operative time. Visualization systems that provide high-definition imaging and 3D endoscopes have improved intraoperative decision-making and reduced reliance on open conversions. Instruments such as graspers, dissectors, and specialized scissors have been iteratively optimized to support port reduction strategies and single-site access without compromising ergonomics.

Third, care delivery models are shifting toward greater decentralization, with ambulatory surgical centers and community hospitals increasingly performing lower-complexity thoracic procedures while tertiary centers focus on high-acuity cases and complex reconstructions. This redistribution of care necessitates product portfolios and training pathways that support scalable adoption across diverse settings. Finally, regulatory attention and payer scrutiny are prompting manufacturers and providers to demonstrate procedure-level value, safety, and reproducibility. Taken together, these shifts are not incremental but systemic: they change how interventions are designed, delivered, and reimbursed, compelling stakeholders to reassess clinical protocols, capital allocation, and training investments.

Supply chain adaptations and procurement strategies responding to tariff shifts that influence sourcing, manufacturing partnerships, and contractual value models

Tariff changes effective in 2025 represent an important external driver influencing supply chain strategy, procurement timing, and cost pass-through across the healthcare ecosystem. In response, manufacturers and institutional purchasing teams have been reassessing sourcing footprints and inventory policies to mitigate exposure to increased import duties and to maintain continuity of critical supplies. This has prompted heightened interest in nearshoring options, diversified supplier networks, and renegotiated contractual terms that emphasize total cost of ownership rather than unit price alone.

Beyond supplier selection, clinicians and operating room managers have begun to evaluate product modularity and reusability as levers to preserve procedural capacity under tighter cost constraints. For example, systems that support a broader range of instruments and consumables offer purchasing efficiencies by reducing the need for multiple single-purpose devices. At the same time, the potential for tariff-driven price adjustments has strengthened collaborative dialogues between device companies and hospital groups about bundled procurement and value-based contracting. These arrangements allow risks to be shared while ensuring access to advanced devices necessary for maintaining clinical quality.

Importantly, the tariff environment also accelerates strategic decisions around local manufacturing partnerships and technology transfer agreements. Stakeholders are increasingly weighing the benefits of establishing assembly or component production within lower-tariff jurisdictions to protect margins and stabilize supply. While these operational shifts do not alter clinical indications or the trajectory of surgical innovation, they do change how quickly new tools are adopted across regions and which suppliers become strategic long-term partners for hospital systems and ambulatory centers alike.

Deep-dive segmentation perspective linking procedural choices, device modality nuances, institutional requirements, and application-specific clinical demands for adoption clarity

Segment analysis provides a lens to understand differentiated adoption patterns, clinical suitability, and purchasing behavior across procedure types, products, end users, technologies, and applications. When examining procedure types, clinicians weigh the trade-offs among robotic assisted thoracoscopic surgery, uniportal VATS, and video-assisted thoracoscopic surgery, balancing factors such as precision, learning curve, and operating room footprint to determine the right fit for institutional case mix. Product portfolios require similar nuance: energy devices including advanced bipolar, electrocautery, and ultrasonic systems are selected based on hemostatic performance and thermal profile, while instruments such as dissectors, graspers, and scissors are assessed for ergonomics and compatibility with port size and approach. Staplers and disposables remain essential for tissue transection and anastomosis, and visualization systems from high-definition platforms to three-dimensional endoscopes and two-dimensional options materially affect intraoperative decision-making and training pathways.

End-user segmentation highlights divergent needs between ambulatory surgical centers and hospitals, where ambulatory settings prioritize streamlined workflows, rapid turnover, and cost-effective disposables, whereas hospitals - encompassing both community hospitals and tertiary care centers - require scalability to support complex resections, multidisciplinary teams, and intensive postoperative care. Technology segmentation illuminates how multi-port systems, robotic systems, and single-port systems each present different capital, maintenance, and training profiles that influence procurement timelines and deployment strategies. Lastly, the application split between diagnostic and therapeutic use cases underscores how instrumentation and visualization choices are driven by whether the primary objective is precise lesion localization or therapeutic resection and reconstruction.

Taken together, segmentation reveals that competitive positioning depends on addressing cross-cutting requirements: clinical efficacy, instrument compatibility across procedural approaches, service and training offerings that reduce the barrier to adoption, and value propositions that resonate with both ambulatory centers and high-volume tertiary hospitals.

How regional healthcare system variation and procurement realities govern technology adoption, training priorities, and commercialization strategies across global markets

Regional dynamics shape technology diffusion, reimbursement pathways, and adoption velocity across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct structural drivers. Stakeholders operating in the Americas often encounter a mixed environment where advanced tertiary centers lead in robotic and single-port adoption while community hospitals and ambulatory centers evaluate cost-effective instrument platforms to expand minimally invasive access. Reimbursement models in this region influence purchasing cycles and the willingness to invest in capital-intensive systems that promise operational efficiencies.

In Europe, Middle East & Africa, variation in health system organization and procurement practices creates a mosaic of adoption trajectories. Some markets emphasize centralized procurement and national-level assessments of clinical benefit, which can either accelerate uptake when evidence is favorable or slow adoption pending cost-effectiveness reviews. Meanwhile, private healthcare segments in parts of the Middle East display rapid uptake of premium platforms aligned with patient demand for advanced care. Across Asia-Pacific, a mix of high-volume surgical centers and rapidly maturing community hospitals drives parallel adoption of refined video-assisted techniques and an increasing interest in robotic platforms where surgical volumes justify the capital outlay. Supply chain resilience and local manufacturing initiatives in this region also play a significant role in shaping commercial strategies and service models.

Overall, regional strategies must be tailored to local reimbursement structures, training ecosystem maturity, and facility-level capabilities. Vendors and health systems that align product configurations, service footprints, and training programs with regional realities can more effectively penetrate diverse markets and support sustainable adoption pathways.

Competitive landscape insights revealing platform incumbency, specialist innovation, and partnership-led strategies that define differentiated market positioning

Competitive dynamics in this field reflect a mix of established platform providers, specialist instrument manufacturers, and emerging firms offering focused innovations in energy, stapling, and visualization. Leading platform providers continue to invest in modularity and interoperability to reduce lock-in and broaden clinical reach, while specialist companies focus on differentiated performance characteristics-such as refined energy profiles, low-profile stapling technologies, or ultra-high-definition three-dimensional imaging-to capture share within specific procedure segments.

Partnerships and collaboration models have become increasingly common as companies seek to combine platform access with best-in-class consumables. Service and training ecosystems are crucial competitive differentiators, as the ability to reduce the learning curve and deliver consistent outcomes influences purchasing decisions by hospitals and ambulatory centers. Moreover, manufacturers that offer comprehensive support programs covering simulation training, proctoring, and performance analytics position themselves as partners in clinical quality improvement rather than mere suppliers.

New entrants are carving out niches by addressing underserved needs, such as cost-sensitive instruments for ambulatory settings or compact visualization systems optimized for single-port workflows. At the same time, incumbents defend their positions by leveraging installed bases, long-term service agreements, and data-driven outcomes evidence. These dynamics mean that competitive advantage increasingly depends on the ability to craft end-to-end value propositions that integrate device performance, clinical training, and commercial flexibility.

Actionable strategic priorities for device developers and health systems to translate technological capability into durable clinical adoption and commercial resilience

Industry leaders should prioritize strategies that align technology development, commercial models, and clinical adoption pathways to accelerate sustainable uptake. First, invest in interoperability and modular architectures that enable instruments and consumables to be used across multiple platforms and procedural approaches, thereby reducing switching costs for hospitals and encouraging broader deployment in community and tertiary settings. Secondly, develop robust training and credentialing programs that combine simulation, proctoring, and post-market analytics to shorten the learning curve for surgeons adopting robotic, uniportal, or advanced video-assisted techniques.

Third, pursue flexible contracting approaches with hospitals and ambulatory centers that incorporate bundled services, outcome-linked clauses, and shared risk elements. These commercial innovations can help mitigate budgetary pressures and create durable procurement relationships. Fourth, strengthen regional go-to-market strategies by tailoring product configurations and support services to local reimbursement realities and supply chain considerations; this is particularly important in markets where local manufacturing partnerships or assembly can materially improve cost competitiveness. Finally, commit to collecting and publishing real-world outcomes that demonstrate comparative effectiveness and safety across procedure types and technologies, which will support clinical adoption and payer dialogues.

By executing these strategic priorities, industry leaders can convert technological capability into sustained clinical impact while addressing the operational and budgetary constraints that influence hospital and ambulatory purchasing decisions.

Integrated mixed-methods approach combining primary stakeholder engagement, clinical evidence review, device assessment, and supply chain analysis for actionable intelligence

This research synthesis draws on a mixed-methods approach combining primary stakeholder interviews, clinical literature review, device and technology assessments, and supply chain analysis to produce an integrated perspective on minimally invasive thoracic surgery. Primary interviews included surgical leaders, hospital procurement executives, ambulatory center administrators, and product managers from device firms to capture real-world decision criteria, adoption barriers, and service expectations. Clinical literature review focused on comparative studies, technique descriptions, and safety analyses to understand how procedural choices map to outcomes and workflow implications.

Device assessments examined design attributes, interoperability, service models, and training offerings to evaluate how product specifications influence adoption in different settings. Supply chain and procurement analyses explored sourcing strategies, tariff exposure, and regional manufacturing considerations to identify operational levers that stakeholders use to manage cost and continuity risk. Where possible, findings were triangulated across data sources to validate patterns and minimize single-source bias.

Throughout the methodology, emphasis was placed on extracting actionable intelligence that supports strategic decision-making rather than producing descriptive lists. Limitations of the approach include variability in regional reporting practices and differences in how institutions capture procedural outcomes, which were addressed by prioritizing triangulated insights and expert validation.

A forward-looking synthesis emphasizing integration of device design, clinical training, and commercial adaptability to ensure broad and sustainable adoption

In sum, minimally invasive thoracic surgery is at an inflection point in which device innovation, procedural refinement, and shifting care delivery models collectively shape the path forward. The interplay among procedure type selection, product capabilities, and institutional readiness determines not only clinical outcomes but also the speed and scale of technology adoption. As supply chain pressures and tariff changes influence commercial dynamics, stakeholders must adopt holistic strategies that align procurement, training, and clinical governance.

Looking ahead, the most successful organizations will be those that integrate modular product design, strong service and training ecosystems, and regionally attuned commercial models. By prioritizing interoperability, real-world evidence generation, and flexible contracting, manufacturers and providers can support broader access to minimally invasive thoracic techniques while managing financial and operational risk. Ultimately, the goal is to ensure that clinical advances translate into measurable improvements in patient care across diverse settings, from ambulatory centers to tertiary hospitals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimally Invasive Thoracic Surgery Market, by Procedure Type

  • 8.1. Lung Resection Procedures
    • 8.1.1. Lobectomy
    • 8.1.2. Segmentectomy
    • 8.1.3. Wedge Resection
    • 8.1.4. Pneumonectomy
    • 8.1.5. Lung Volume Reduction Surgery
  • 8.2. Esophageal Procedures
    • 8.2.1. Esophagectomy
    • 8.2.2. Anti-Reflux Surgery
    • 8.2.3. Myotomy
  • 8.3. Mediastinal Procedures
    • 8.3.1. Thymectomy
    • 8.3.2. Mediastinal Tumor Resection
    • 8.3.3. Lymph Node Dissection
  • 8.4. Pleural Procedures
    • 8.4.1. Pleurodesis
    • 8.4.2. Decortication
    • 8.4.3. Bullectomy
    • 8.4.4. Pleural Biopsy
  • 8.5. Sympathetic Procedures

9. Minimally Invasive Thoracic Surgery Market, by Product Type

  • 9.1. Surgical Systems
    • 9.1.1. Thoracoscopic Video Systems
    • 9.1.2. Robotic Surgical Platforms
  • 9.2. Surgical Instruments
    • 9.2.1. Endoscopic Hand Instruments
    • 9.2.2. Endoscopic Stapling Devices
    • 9.2.3. Energy Devices
      • 9.2.3.1. Electrosurgical Devices
      • 9.2.3.2. Ultrasonic Devices
      • 9.2.3.3. Advanced Bipolar Devices
    • 9.2.4. Suction-Irrigation Devices
  • 9.3. Access Devices
    • 9.3.1. Trocars & Ports
    • 9.3.2. Access Needles
    • 9.3.3. Wound Protectors
  • 9.4. Closure & Hemostasis Products
    • 9.4.1. Sutures & Clips
    • 9.4.2. Staple Line Reinforcement Materials
    • 9.4.3. Sealants & Hemostatic Agents
  • 9.5. Imaging & Navigation
    • 9.5.1. Intraoperative Imaging Systems
    • 9.5.2. Fluorescence Imaging Systems
    • 9.5.3. Navigation & Mapping Systems

10. Minimally Invasive Thoracic Surgery Market, by Indication

  • 10.1. Malignant Thoracic Diseases
    • 10.1.1. Primary Lung Cancer
      • 10.1.1.1. Early-Stage Non-Small Cell Lung Cancer
      • 10.1.1.2. Locally Advanced Non-Small Cell Lung Cancer
    • 10.1.2. Metastatic Lung Lesions
    • 10.1.3. Esophageal Cancer
    • 10.1.4. Mediastinal Malignancies
  • 10.2. Benign Thoracic Diseases
    • 10.2.1. Pneumothorax
    • 10.2.2. Empyema
    • 10.2.3. Benign Esophageal Disorders
      • 10.2.3.1. Gastroesophageal Reflux Disease
      • 10.2.3.2. Achalasia
    • 10.2.4. Mediastinal Cysts And Benign Tumors
    • 10.2.5. Hyperhidrosis
    • 10.2.6. Benign Pulmonary Nodules

11. Minimally Invasive Thoracic Surgery Market, by End User

  • 11.1. Hospitals
    • 11.1.1. Tertiary Care Hospitals
    • 11.1.2. Community Hospitals
    • 11.1.3. Specialty Thoracic Centers
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Specialty Clinics
  • 11.4. Academic And Research Institutes

12. Minimally Invasive Thoracic Surgery Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Minimally Invasive Thoracic Surgery Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Minimally Invasive Thoracic Surgery Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Minimally Invasive Thoracic Surgery Market

16. China Minimally Invasive Thoracic Surgery Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. B. Braun Melsungen AG
  • 17.6. Becton, Dickinson and Company
  • 17.7. Boston Scientific Corporation
  • 17.8. Cardio Medical GmbH
  • 17.9. CONMED Corporation
  • 17.10. Cook Medical LLC
  • 17.11. Dextera Surgical, Inc.
  • 17.12. Fujifilm Holdings Corporation
  • 17.13. GE HealthCare, Inc.
  • 17.14. Grena Ltd.
  • 17.15. Intuitive Surgical, Inc.
  • 17.16. Johnson & Johnson
  • 17.17. KARL STORZ SE & Co. KG
  • 17.18. Koninklijke Philips N.V.
  • 17.19. LivaNova plc
  • 17.20. Medela Healthcare
  • 17.21. Medtronic plc
  • 17.22. Merit Medical Systems, Inc.
  • 17.23. Olympus Corporation
  • 17.24. Sklar Surgical Instruments
  • 17.25. Smith & Nephew plc
  • 17.26. Stryker Corporation
  • 17.27. Teleflex Incorporated
  • 17.28. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LOBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LOBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LOBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SEGMENTECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SEGMENTECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SEGMENTECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY WEDGE RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY WEDGE RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY WEDGE RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PNEUMONECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PNEUMONECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PNEUMONECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ANTI-REFLUX SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ANTI-REFLUX SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ANTI-REFLUX SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MYOTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MYOTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MYOTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY THYMECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY THYMECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY THYMECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL TUMOR RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL TUMOR RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL TUMOR RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LYMPH NODE DISSECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LYMPH NODE DISSECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LYMPH NODE DISSECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURODESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURODESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURODESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY DECORTICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY DECORTICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY DECORTICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BULLECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BULLECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BULLECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SYMPATHETIC PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SYMPATHETIC PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SYMPATHETIC PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY THORACOSCOPIC VIDEO SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY THORACOSCOPIC VIDEO SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY THORACOSCOPIC VIDEO SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ROBOTIC SURGICAL PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ROBOTIC SURGICAL PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ROBOTIC SURGICAL PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENDOSCOPIC HAND INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENDOSCOPIC HAND INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENDOSCOPIC HAND INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENDOSCOPIC STAPLING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENDOSCOPIC STAPLING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENDOSCOPIC STAPLING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ULTRASONIC DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ULTRASONIC DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ULTRASONIC DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUCTION-IRRIGATION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUCTION-IRRIGATION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUCTION-IRRIGATION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY TROCARS & PORTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY TROCARS & PORTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY TROCARS & PORTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS NEEDLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS NEEDLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS NEEDLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY WOUND PROTECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY WOUND PROTECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY WOUND PROTECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUTURES & CLIPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUTURES & CLIPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUTURES & CLIPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY STAPLE LINE REINFORCEMENT MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY STAPLE LINE REINFORCEMENT MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY STAPLE LINE REINFORCEMENT MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SEALANTS & HEMOSTATIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SEALANTS & HEMOSTATIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SEALANTS & HEMOSTATIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INTRAOPERATIVE IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INTRAOPERATIVE IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INTRAOPERATIVE IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY FLUORESCENCE IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY FLUORESCENCE IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY FLUORESCENCE IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY NAVIGATION & MAPPING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY NAVIGATION & MAPPING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY NAVIGATION & MAPPING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY EARLY-STAGE NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY EARLY-STAGE NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY EARLY-STAGE NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY METASTATIC LUNG LESIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY METASTATIC LUNG LESIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY METASTATIC LUNG LESIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PNEUMOTHORAX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PNEUMOTHORAX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PNEUMOTHORAX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY EMPYEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY EMPYEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY EMPYEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACHALASIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACHALASIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACHALASIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL CYSTS AND BENIGN TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL CYSTS AND BENIGN TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL CYSTS AND BENIGN TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HYPERHIDROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HYPERHIDROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HYPERHIDROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN PULMONARY NODULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN PULMONARY NODULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN PULMONARY NODULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SPECIALTY THORACIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SPECIALTY THORACIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SPECIALTY THORACIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MEDIASTINAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PLEURAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 246. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 248. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY SURGICAL INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ACCESS DEVICES, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY CLOSURE & HEMOSTASIS PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY IMAGING & NAVIGATION, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY MALIGNANT THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PRIMARY LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN THORACIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY BENIGN ESOPHAGEAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY LUNG RESECTION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA MINIMALLY INVASIVE THORACIC SURGERY MARKET SIZE, BY ESOPHAGEAL PROCEDURES